Let’s Keep the Door to Biotechnological Eugenics Closed
By Enola Aird,
MomsRising
| 02. 10. 2014
Remember the
three-parent babies I told you about in December? The ones made with genetic material from two different women? Well, the United States might be moving a step closer to their creation.
A Food and Drug Administration (FDA) Advisory Committee will hold a
public meeting on February 25 and 26 regarding clinical trials of mitochondrial transfer procedures (MT). I’ve submitted a written
statement and received FDA permission to present my arguments at the meeting. I’ll be there to oppose the use of such procedures because they would permanently change the genes passed down to future generations.
A quick reminder of what’s at stake. The Advisory Committee will consider whether to allow human clinical trials of “oocyte modification in assisted reproduction for the prevention of the transmission of mitochondrial disease or treatment of infertility.” That’s a long way of referring to a form of genetic modification that would alter an embryo’s genetic structure in such a way that the changes would be passed down to all future generations of the same line.
To accomplish this sci-fi sounding task, scientists would...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Patrick Foong, BioNews | 11.03.2025
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...